효소 대체 요법(ERT) 시장 규모, 점유율, 성장 및 세계 업계 분석 : 유형 및 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of enzyme replacement therapy (ERT) Market

The global enzyme replacement therapy (ERT) market is projected to witness robust growth in the coming years, driven by the rising prevalence of rare, chronic, and inherited disorders, along with increasing healthcare access and advanced treatment options. According to a recent market report, the global enzyme replacement therapy market size was valued at USD 15.89 billion in 2025. The market is expected to grow to USD 17.3 billion in 2026 and further reach USD 35.67 billion by 2034, exhibiting a CAGR of 9.46% from 2026 to 2034.

Enzyme replacement therapy involves the administration of specific enzymes to patients with enzyme deficiencies or related disorders. Its growing adoption is largely fueled by the prevalence of lysosomal storage disorders (LSDs) such as Gaucher disease, Fabry disease, and Pompe disease. For instance, in the United States, approximately 6,000 individuals were reported to have Gaucher disease in 2020, with 95% affected by Type 1.

Key Market Drivers

The growth of the ERT market is primarily driven by the increasing prevalence of rare disorders, continuous approvals of advanced therapy products, and improved healthcare infrastructure. Leading companies such as BioMarin, Sanofi, and Takeda Pharmaceutical Company Limited have been actively introducing innovative enzyme therapies. In July 2019, Takeda launched Idursulfase, Velaglucerase Alpha, and Agalsidase Alfa in India for treating Hunter syndrome, Gaucher disease, and Fabry disease. Furthermore, favorable reimbursement policies in developed countries and increased patient awareness are accelerating adoption rates.

During the COVID-19 pandemic, ERT experienced a positive impact due to increased sales of related drugs and the expansion of homecare initiatives for therapy administration. From 2022 onwards, rising drug sales and patient demand for advanced therapies have supported consistent market growth.

Market Segmentation Analysis

By Drug Class: In 2026, pancrelipase dominated the ERT market with a 24.13% share, primarily due to its use in treating Exocrine Pancreatic Insufficiency (EPI) among chronic pancreatitis and cystic fibrosis patients. The agalsidase segment ranked second, reflecting high costs and increasing demand for Fabry disease treatment. Collaborative initiatives, such as the 2024 partnership between mAbxience and Biosidus to produce Agalsidase Beta, are further driving growth.

By Route of Administration: The parenteral segment is expected to account for 75.87% of the market in 2026, owing to advantages like direct bloodstream delivery, consistent dosing, and suitability for patients with gastrointestinal issues. Oral administration holds a smaller share due to limited availability of oral formulations for LSDs.

By Indication: EPI held the largest share at 24.13% in 2026, supported by high prevalence rates in patients with chronic pancreatitis and cystic fibrosis. Emerging rare genetic and lysosomal disorders drive growth in the "others" category, including therapies like Brineura for Neuronal ceroid lipofuscinosis type 2.

By End User: The homecare settings & infusion centers segment is projected to grow the fastest, capturing 69.23% of the market in 2026, as patients increasingly prefer home-based treatments for convenience, cost-effectiveness, and safety. Hospitals remain important but grow at a moderate pace due to limited capacity and specialized infrastructure requirements.

Regional Insights

In 2025, North America dominated the market with USD 7.57 billion, representing 47.61% of global revenue. The U.S. market is projected to reach USD 7.62 billion in 2026, supported by 3,600 infusion centers and government reimbursement programs. Europe accounted for USD 4.56 billion in 2025 and is expected to reach USD 5 billion in 2026, with strong support from reimbursement programs in countries like Poland and Germany. Asia Pacific reached USD 2.58 billion in 2025 and is estimated at USD 2.86 billion in 2026, driven by improving diagnostics, government initiatives, and rising awareness in Japan, China, and India. Latin America and Middle East & Africa collectively held smaller market shares but are projected to grow steadily, with 2025 values of USD 0.78 billion and USD 0.4 billion, respectively.

Key Players and Industry Developments

Leading companies maintaining dominance include BioMarin, Sanofi, AbbVie Inc., Takeda, Pfizer Inc., and JCR Pharmaceuticals Co., Ltd. Strategic partnerships, acquisitions, and regulatory approvals are central to sustaining market leadership. Notable developments include:

• November 2023: FDA approval of ADZYNMA by Takeda for congenital thrombotic thrombocytopenic purpura.
• September 2023: FDA approval of Pombiliti + Opfolda for late-onset Pompe disease by Amicus Therapeutics.
• January 2021: Clinigen Group obtained approval for Hunterase ICV in Japan.

Conclusion

The global enzyme replacement therapy market is poised for substantial growth between 2025 and 2034. Increasing prevalence of rare disorders, rising homecare adoption, and consistent innovations by key market players are driving the market forward. North America continues to dominate, while emerging regions in Asia Pacific show promising expansion opportunities. With enhanced regulatory approvals, reimbursement policies, and patient awareness initiatives, the market is expected to more than double by 2034, reaching USD 35.67 billion.

Segmentation By Drug Class

• Alglucosidase alfa
• Agalsidase
• Pancrelipase
• Idursulfase
• Laronidase
• Imiglucerase
• Elosulfase alfa
• Asfotase alfa
• Galsulfase
• Velaglucerase alfa
• Others

By Route of Administration

• Parenteral
• Oral

By Indication

• Type 1 Gaucher disease
• Pompe Disease
• MPS (Mucopolysaccharidosis)
• Exocrine Pancreatic Insufficiency (EPI)
• Fabry Disease
• Hypophosphatasia
• Others

By End User

• Hospitals
• Homecare settings & Infusion Centers

By Geography

• North America (By Drug Class, By Route of Administration, By Indication, By End User, and By Country)
  • U.S. (By Indication)
  • Canada (By Indication)
• Europe (By Drug Class, By Route of Administration, By Indication, By End User, and By Country /Sub-region)
  • U.K. (By Indication)
  • Germany (By Indication)
  • France (By Indication)
  • Italy (By Indication)
  • Spain (By Indication)
  • Scandinavia (By Indication)
  • Rest of Europe (By Indication)
• Asia Pacific (By Drug Class, By Route of Administration, By Indication, By End User, and By Country/Sub-region)
  • Japan (By Indication)
  • China (By Indication)
  • India (By Indication)
  • Australia (By Indication)
  • Southeast Asia (By Indication)
  • Rest of Asia Pacific (By Indication)
• Latin America (By Drug Class, By Route of Administration, By Indication, By End User, and By Country /Sub-region)
  • Brazil (By Indication)
  • Mexico (By Indication)
  • Rest of Latin America (By Indication)
• Middle East& Africa (By Drug Class, By Route of Administration, By Indication, By End User, and By Country /Sub-region)
  • South Africa (By Indication)
  • GCC (By Indication)
  • Rest of Middle East & Africa (By Indication)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Disorders, By Key Countries/Regions, 2025
• 4.2. New Product Launches, By Key Players
• 4.3. Key Industry Developments - Mergers, Acquisitions, etc.
• 4.4. Impact of COVID-19 on the Enzyme Replacement Therapy Market

5. Global Enzyme Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug Class
  • 5.1.1. Alglucosidase alfa
  • 5.1.2. Agalsidase
  • 5.1.3. Pancrelipase
  • 5.1.4. Idursulfase
  • 5.1.5. Laronidase
  • 5.1.6. Imiglucerase
  • 5.1.7. Elosulfase alfa
  • 5.1.8. Asfotase alfa
  • 5.1.9. Galsulfase
  • 5.1.10. Velaglucerase alfa
  • 5.1.11. Others
• 5.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.2.1. Parenteral
  • 5.2.2. Oral
• 5.3. Market Analysis, Insights and Forecast - By Indication
  • 5.3.1. Type 1 Gaucher disease
  • 5.3.2. Pompe Disease
  • 5.3.3. MPS (Mucopolysaccharidosis)
  • 5.3.4. Exocrine Pancreatic Insufficiency (EPI)
  • 5.3.5. Fabry Disease
  • 5.3.6. Hypophosphatasia
  • 5.3.7. Others
• 5.4. Market Analysis, Insights and Forecast - By End User
  • 5.4.1. Hospitals
  • 5.4.2. Homecare settings & Infusion Centers
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Enzyme Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug Class
  • 6.1.1. Alglucosidase alfa
  • 6.1.2. Agalsidase
  • 6.1.3. Pancrelipase
  • 6.1.4. Idursulfase
  • 6.1.5. Laronidase
  • 6.1.6. Imiglucerase
  • 6.1.7. Elosulfase alfa
  • 6.1.8. Asfotase alfa
  • 6.1.9. Galsulfase
  • 6.1.10. Velaglucerase alfa
  • 6.1.11. Others
• 6.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.2.1. Parenteral
  • 6.2.2. Oral
• 6.3. Market Analysis, Insights and Forecast - By Indication
  • 6.3.1. Type 1 Gaucher disease
  • 6.3.2. Pompe Disease
  • 6.3.3. MPS (Mucopolysaccharidosis)
  • 6.3.4. Exocrine Pancreatic Insufficiency (EPI)
  • 6.3.5. Fabry Disease
  • 6.3.6. Hypophosphatasia
  • 6.3.7. Others
• 6.4. Market Analysis, Insights and Forecast - By End User
  • 6.4.1. Hospitals
  • 6.4.2. Homecare settings & Infusion Centers
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
    • 6.5.1.1. By Indication
  • 6.5.2. Canada
    • 6.5.2.1. By Indication

7. Europe Enzyme Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug Class
  • 7.1.1. Alglucosidase alfa
  • 7.1.2. Agalsidase
  • 7.1.3. Pancrelipase
  • 7.1.4. Idursulfase
  • 7.1.5. Laronidase
  • 7.1.6. Imiglucerase
  • 7.1.7. Elosulfase alfa
  • 7.1.8. Asfotase alfa
  • 7.1.9. Galsulfase
  • 7.1.10. Velaglucerase alfa
  • 7.1.11. Others
• 7.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.2.1. Parenteral
  • 7.2.2. Oral
• 7.3. Market Analysis, Insights and Forecast - By Indication
  • 7.3.1. Type 1 Gaucher disease
  • 7.3.2. Pompe Disease
  • 7.3.3. MPS (Mucopolysaccharidosis)
  • 7.3.4. Exocrine Pancreatic Insufficiency (EPI)
  • 7.3.5. Fabry Disease
  • 7.3.6. Hypophosphatasia
  • 7.3.7. Others
• 7.4. Market Analysis, Insights and Forecast - By End User
  • 7.4.1. Hospitals
  • 7.4.2. Homecare settings & Infusion Centers
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 7.5.1. U.K
    • 7.5.1.1. By Indication
  • 7.5.2. Germany
    • 7.5.2.1. By Indication
  • 7.5.3. France
    • 7.5.3.1. By Indication
  • 7.5.4. Italy
    • 7.5.4.1. By Indication
  • 7.5.5. Spain
    • 7.5.5.1. By Indication
  • 7.5.6. Scandinavia
    • 7.5.6.1. By Indication
  • 7.5.7. Rest of Europe
    • 7.5.7.1. By Indication

8. Asia Pacific Enzyme Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug Class
  • 8.1.1. Alglucosidase alfa
  • 8.1.2. Agalsidase
  • 8.1.3. Pancrelipase
  • 8.1.4. Idursulfase
  • 8.1.5. Laronidase
  • 8.1.6. Imiglucerase
  • 8.1.7. Elosulfase alfa
  • 8.1.8. Asfotase alfa
  • 8.1.9. Galsulfase
  • 8.1.10. Velaglucerase alfa
  • 8.1.11. Others
• 8.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.2.1. Parenteral
  • 8.2.2. Oral
• 8.3. Market Analysis, Insights and Forecast - By Indication
  • 8.3.1. Type 1 Gaucher disease
  • 8.3.2. Pompe Disease
  • 8.3.3. MPS (Mucopolysaccharidosis)
  • 8.3.4. Exocrine Pancreatic Insufficiency (EPI)
  • 8.3.5. Fabry Disease
  • 8.3.6. Hypophosphatasia
  • 8.3.7. Others
• 8.4. Market Analysis, Insights and Forecast - By End User
  • 8.4.1. Hospitals
  • 8.4.2. Homecare settings & Infusion Centers
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 8.5.1. Japan
    • 8.5.1.1. By Indication
  • 8.5.2. China
    • 8.5.2.1. By Indication
  • 8.5.3. India
    • 8.5.3.1. By Indication
  • 8.5.4. Australia
    • 8.5.4.1. By Indication
  • 8.5.5. Southeast Asia
    • 8.5.5.1. By Indication
  • 8.5.6. Rest of Asia Pacific
    • 8.5.6.1. By Indication

9. Latin America Enzyme Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug Class
  • 9.1.1. Alglucosidase alfa
  • 9.1.2. Agalsidase
  • 9.1.3. Pancrelipase
  • 9.1.4. Idursulfase
  • 9.1.5. Laronidase
  • 9.1.6. Imiglucerase
  • 9.1.7. Elosulfase alfa
  • 9.1.8. Asfotase alfa
  • 9.1.9. Galsulfase
  • 9.1.10. Velaglucerase alfa
  • 9.1.11. Others
• 9.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.2.1. Parenteral
  • 9.2.2. Oral
• 9.3. Market Analysis, Insights and Forecast - By Indication
  • 9.3.1. Type 1 Gaucher disease
  • 9.3.2. Pompe Disease
  • 9.3.3. MPS (Mucopolysaccharidosis)
  • 9.3.4. Exocrine Pancreatic Insufficiency (EPI)
  • 9.3.5. Fabry Disease
  • 9.3.6. Hypophosphatasia
  • 9.3.7. Others
• 9.4. Market Analysis, Insights and Forecast - By End User
  • 9.4.1. Hospitals
  • 9.4.2. Homecare settings & Infusion Centers
• 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.5.1. Brazil
    • 9.5.1.1. By Indication
  • 9.5.2. Mexico
    • 9.5.2.1. By Indication
  • 9.5.3. Rest of Latin America
    • 9.5.3.1. By Indication

10. Middle East & Africa Enzyme Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Drug Class
  • 10.1.1. Alglucosidase alfa
  • 10.1.2. Agalsidase
  • 10.1.3. Pancrelipase
  • 10.1.4. Idursulfase
  • 10.1.5. Laronidase
  • 10.1.6. Imiglucerase
  • 10.1.7. Elosulfase alfa
  • 10.1.8. Asfotase alfa
  • 10.1.9. Galsulfase
  • 10.1.10. Velaglucerase alfa
  • 10.1.11. Others
• 10.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.2.1. Parenteral
  • 10.2.2. Oral
• 10.3. Market Analysis, Insights and Forecast - By Indication
  • 10.3.1. Type 1 Gaucher disease
  • 10.3.2. Pompe Disease
  • 10.3.3. MPS (Mucopolysaccharidosis)
  • 10.3.4. Exocrine Pancreatic Insufficiency (EPI)
  • 10.3.5. Fabry Disease
  • 10.3.6. Hypophosphatasia
  • 10.3.7. Others
• 10.4. Market Analysis, Insights and Forecast - By End User
  • 10.4.1. Hospitals
  • 10.4.2. Homecare settings & Infusion Centers
• 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.5.1. GCC
    • 10.5.1.1. By Indication
  • 10.5.2. South Africa
    • 10.5.2.1. By Indication
  • 10.5.3. Rest of Middle East & Africa
    • 10.5.3.1. By Indication

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. BioMarin
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & Services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Leadiant Biosciences, Inc.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & Services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Pfizer Inc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & Services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Sanofi
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & Services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. AbbVie Inc.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & Services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Takeda Pharmaceutical Company Limited
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & Services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. JCR Pharmaceutical Co., Ltd.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & Services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Nestle
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & Services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)